The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders DOI Creative Commons
Al-Hassan Soliman Wadan, Mostafa K. Abd El‐Aziz, Doha El‐Sayed Ellakwa

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Abstract The modulation of gut microbiota presents promising therapeutic possibilities for various health conditions, ranging from gastrointestinal infections to neurodegenerative and mental disorders. Among the available interventions, modulators (GMMs) such as probiotics prebiotics have demonstrated significant potential in infection prevention neuroprotection. Despite these encouraging findings, clinical application GMMs remains challenging due safety concerns inconsistent effectiveness across diverse patient populations. These factors create substantial barriers widespread adoption microbiota-based therapies practice. To overcome challenges fully leverage modulation, this review explores feasibility repurposing managing multiple A broad spectrum microbiota-targeted strategies is examined, including dietary modifications, fecal transplantation, bacteriophage therapy, microbiome engineering, immune system modulation. particularly innovative approach involves integrating with pharmaceutical delivery systems enhance efficacy while mitigating adverse effects. This integrative strategy underscores pivotal role disease, supporting development precision medicine tailored individual needs. By combining targeted mechanisms, not only improves treatment but also addresses critical regarding variability. Furthermore, outlines future research directions within rapidly evolving field emphasizing necessity comprehensive trials long-term evaluations. critically assessing both opportunities associated study provides a strategic framework translating experimental into viable applications. holistic has redefine paradigms, offering personalized wide range disorders advancing broader medicine.

Language: Английский

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions DOI

Yumna Khan,

Sana Rizvi, Ali Raza

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Language: Английский

Citations

2
The Interplay of Mitochondrial Dysfunction in Oral Diseases: Recent Updates in Pathogenesis and Therapeutic Implications DOI

Al-Hassan Soliman Wadan,

Mohamed Abdelsattar Ahmed,

Abdelnaser Hussein Ahmed

et al.

Mitochondrion, Journal Year: 2024, Volume and Issue: 78, P. 101942 - 101942

Published: Aug. 6, 2024

Language: Английский

Citations

10
Response of different infection models in broiler chickens against supplemental Organic acid – A review DOI
Roshan Riaz, İbrar Ahmed, Ali Raza

et al.

Microbial Pathogenesis, Journal Year: 2025, Volume and Issue: unknown, P. 107527 - 107527

Published: April 1, 2025

Language: Английский

Citations

1
Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria DOI

Fatima Mourabiti,

Fatimazahra Jouga,

Souraya Sakoui

et al.

Archives of Microbiology, Journal Year: 2025, Volume and Issue: 207(3)

Published: Feb. 13, 2025

Language: Английский

Citations

0
Characteristics and Outcomes of Patients Treated with Carbapenem Versus Non-carbapenem Therapy for AmpC-Producing Enterobacterales Bacteremia: A Retrospective Study DOI Creative Commons
Shuroug A. Alowais, Atheer Aldairem, Sumaya N. Almohareb

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Inducible AmpC β-lactamases in Gram-negative Enterobacterales pose therapeutic challenges. Although carbapenems are the preferred treatment, other antibiotics can serve as a viable alternative. Studies comparing treatment options report varied outcomes. This study evaluates 30-day mortality, failure, and length of hospitalization patients with AmpC-producing bacteremia. retrospective cohort included adult bacteremia caused by Enterobacterales. Exclusion criteria included: therapy duration < 72 h, coinfection, resistant isolates, death within h diagnosis. Patients were divided into definitive carbapenem noncarbapenem therapy. The primary outcome was while secondary outcomes evaluated failure hospitalization. Statistical analysis used descriptive statistics, group comparisons, logistic regression. Of 214 screened patients, 80 met inclusion criteria. Enterobacter cloacae (60%) predominant pathogen, primarily originating from line-related infections (55%). Carbapenems empirical (45%) (75%) therapies; mortality higher non-carbapenem (20% versus 3.3%, p = 0.08). Treatment significantly 1.6%, 0.01). mean hospital stay longer (26 ± 38.40 days) than (11.15 7.15 days, 0.87). Older age associated (odds ratio (OR) 1.07, 95% confidence intervals (CI): 0.98-12.20, 0.015). Carbapenem use improved survival, highlighting its importance strategies. Age affects stressing need for personalized treatments. Further research strategies needed to address clinical failures enhance antimicrobial stewardship.

Language: Английский

Citations

0
A Review of In Silico and In Vitro Approaches in the Fight Against Carbapenem‐Resistant Enterobacterales DOI Creative Commons

Muhammad Absar,

Abdul Rahman Zaidah, Amer Mahmood

et al.

Journal of Clinical Laboratory Analysis, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

ABSTRACT Objectives The rise in carbapenem‐resistant Enterobacterales (CRE) has reinforced the global quest for developing effective therapeutics. Traditional drug discovery approaches have been inadequate overcoming this challenge due to their resource and time constraints. Methods English literature was searched by structured queries related our review between January 1, 2020, December 31, 2024. Results key resistance mechanisms CRE, such as enzymatic hydrolysis, decreased permeability, efflux pump overexpression, examined review. Computational technologies become pivotal discovering novel antimicrobial agents with improved accuracy efficiency. Besides this, highlights advances structure‐ ligand‐based identifying potential drugs against CRE. Recent studies demonstrating use of silico techniques develop targeted CRE also explored. Moreover, underscores significance integrating both vitro counter Enterobacterales, supported latest studies. However, these promising computational a few major drawbacks, lack standardized parameterization, potentially false positives, complexity clinical translations. regulatory barriers restrict progress new antimicrobials market approval. Conclusion inhibitor is gaining popularity, it can be expedited refining them reliable validation. innovative hybrid need hour tackle mitigate threat resistance.

Language: Английский

Citations

0
Insight into bioactive glass and bio-ceramics uses: unveiling recent advances for biomedical application DOI Creative Commons
Doha El‐Sayed Ellakwa,

Ahmad S. Abu‐Khadra,

Takwa E. Ellakwa

et al.

Discover Materials, Journal Year: 2025, Volume and Issue: 5(1)

Published: April 25, 2025

Language: Английский

Citations

0
The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders DOI Creative Commons
Al-Hassan Soliman Wadan, Mostafa K. Abd El‐Aziz, Doha El‐Sayed Ellakwa

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Abstract The modulation of gut microbiota presents promising therapeutic possibilities for various health conditions, ranging from gastrointestinal infections to neurodegenerative and mental disorders. Among the available interventions, modulators (GMMs) such as probiotics prebiotics have demonstrated significant potential in infection prevention neuroprotection. Despite these encouraging findings, clinical application GMMs remains challenging due safety concerns inconsistent effectiveness across diverse patient populations. These factors create substantial barriers widespread adoption microbiota-based therapies practice. To overcome challenges fully leverage modulation, this review explores feasibility repurposing managing multiple A broad spectrum microbiota-targeted strategies is examined, including dietary modifications, fecal transplantation, bacteriophage therapy, microbiome engineering, immune system modulation. particularly innovative approach involves integrating with pharmaceutical delivery systems enhance efficacy while mitigating adverse effects. This integrative strategy underscores pivotal role disease, supporting development precision medicine tailored individual needs. By combining targeted mechanisms, not only improves treatment but also addresses critical regarding variability. Furthermore, outlines future research directions within rapidly evolving field emphasizing necessity comprehensive trials long-term evaluations. critically assessing both opportunities associated study provides a strategic framework translating experimental into viable applications. holistic has redefine paradigms, offering personalized wide range disorders advancing broader medicine.

Language: Английский

Citations

0